Results 71 to 80 of about 51,600 (308)

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Appropriate Medical Therapy Primarily Modifies Type 2 and Severity Biomarkers in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral ...
Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan   +9 more
wiley   +1 more source

Sputum immunoglobulin E levels correlate with eosinophilic airway regardless of atopy

Allergy, Asthma & Clinical Immunology
Immunoglobulin E (IgE) is a key molecule that induces mast cell activation in allergic inflammation and contributes to type 2/eosinophilic inflammation in asthmatic airways.
Hyo-In Rhyou, Thi Bich Tra Cao, Quang Luu Quoc, Young-Hee Nam, Hae-Sim Park   +4 more
doaj   +1 more source

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman, Spencer Short, Emma Tam, Benjamin F. Bitner, Abdulghafoor Alani, Marc Rosen, Mindy Rabinowitz, Damaris Pena Evertz, Elina Toskala, Gurston G. Nyquist   +9 more
wiley   +1 more source

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.

PLoS ONE, 2021
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi, Hironori Masuko, Yohei Yatagai, Takefumi Saito, Nobuyuki Hizawa   +10 more
doaj   +1 more source

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke, Edris Mohamed, Ahmed, Joos, Guy, Lahousse, Lies, Maes, Tania   +4 more
core   +1 more source

Biological therapies for eosinophilic asthma [PDF]

Expert Opinion on Biological Therapy, 2018
Severe uncontrolled asthma is by definition refractory to traditional therapies or can be controlled only with therapies that have intolerable side effects. Monoclonal antibodies that target interleukin (IL)-5/IL-5Rα, IgE, and IL-4Rα have shown favorable results in clinical trials, including reductions in asthma exacerbations and other important ...
Shiven S, Patel, Thomas B, Casale, Juan Carlos, Cardet   +2 more
openaire   +2 more sources

Rationale of New Grading System: Central Compartment Atopic Disease

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Central compartment atopic disease (CCAD) has recently been recognized as a distinct phenotype within the spectrum of type 2–dominant chronic rhinosinusitis (CRS). Although international guidelines highlight polypoid changes in the central nasal cavity, standardized diagnostic and classification criteria are still lacking.
Ramón Moreno‐Luna, Carmen Palma‐Martínez, Serafin Sánchez‐Gómez, Isam Alobid, Daniel Martin‐Jimenez, José Miguel Villacampa‐Aubá, Christian Calvo‐Henríquez, Alfonso Del Cuvillo, Alfonso Santamaría‐Gadea, Jaime González‐García, Richard J. Harvey, John M. DelGaudio   +11 more
wiley   +1 more source

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion

Respiratory Medicine Case Reports, 2019
We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma.
Khodr Tello, Andreas Hoffmann, Björn Beutel, Timm Greulich, Claus Franz Vogelmeier, Manuel Jonas Richter, Stefan Kuhnert, Tobias Böselt, Peter Alter, Angelique Holland, Marco Idzko, Roland Buhl, Andreas Rembert Koczulla   +12 more
doaj   +1 more source

The effects of anti-sense interleukin-5 gene transferred by recombinant adeno-associated virus in allergic rats [PDF]

, 2008
The accumulation and infiltration of eosinophils in airways is one of the most important characteristics of asthma, and is mediated partly by secretion of IL-5 from Th2 lymphocytes.
Chao Cao, Daxiong Zeng, Qingfeng Song, Weining Xiong, Xiansheng Liu, Yong Cao, Yongjian Xu   +6 more
core   +1 more source